Vaccines
An Introduction to Vaccines
Vaccines have substantially reduced morbidity and mortality from infectious diseases in the developed world. Many vaccines, including those for measles and some influenza vaccines, use live attenuated viruses. The COVID-19 pandemic has led to unprecedented rates of vaccine development, raising hopes that other vaccines might be made on a comparable timescale in the future. In particular, it has established the clinical utility of mRNA vaccines,
which have demonstrated high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. In addition, other approaches, including nucleic acid-based vaccines, recombinant DNA platforms, virus-like particle (VLP) based vaccines, non-replicating viral vectors, recombinant nanoparticles and peptide vaccines in active clinical development.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
The World Vaccine Congress Washington 2025, 21-24 April 2025, delivered another landmark year, bringing together more than 4,000 global stakeholders from biotechnology, pharmaceuticals, government, academia and the broader global health ecosystem. The event reinforced its standing as an influential and collaborative forum in ...
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
The US Food and Drug Administration (FDA) has approved the first virus-like particle (VLP) chikungunya vaccine PXVX0317 (VIMKUNYA™), for individuals aged 12 years and older, with Bavarian Nordic recently announcing its commercial launch.1,2 This approval addresses a critical unmet need for ...
"Europe remains committed to the global fight to end polio once and for all" Polio may be a distant memory for many in Europe, but the virus is far from gone. New data reveal that vaccine-derived poliovirus type 2 (VDPV2) was ...
Mpox is endemic in the Democratic Republic of the Congo (DRC), with cases rising over the past decade. Children were the most severely affected in the 2023 outbreak, which saw over 14,000 cases and 600 deaths.1 Despite the deployment of the modified vaccinia ...
Vaccination strategies for pneumococcal disease: Update and perspectives on clinical need and impact
Prof. Torres discusses the evolution of pneumococcal disease and the impact of novel vaccination strategies.
The start-to-finish of vaccines: Innovation and challenges at the World Vaccine Congress Europe 2024
The European Region is a global vaccine leader, boasting a “strong research ecosystem” and a competitive market, expected to achieve a volume of €16.32 billion by 2029. Through efforts to keep pace with the “unprecedented acceleration” of life science innovation, the landscape attracts investment and political support as leaders recognise the value of vaccination as a cost-effective intervention and a means of demonstrating health leadership.
In a real-world study from Ontario, researchers confirmed that a single dose of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine offers 58% protection against mpox infection.
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) hosted its 2024 Global Congress in Barcelona, continuing its tradition of presenting high-quality data and fostering insightful discussions.
Sponsored content from GSK. Watch leading experts Jeremy Szeto and Kristen Robillard discuss their personal experience with adult immunization programs and the approaches they use in their practices to help optimize adult immunization rates.
HIV vaccine development harnesses breakthroughs in structure-based antigen design, sequencing, and single-cell analysis to create potent vaccines. Prof. Barney Graham, Professor of Medicine, Microbiology, Chemistry and Immunology, Morehouse School of Medicine in Atlanta, Georgia, USA explores advances reported at CROI 2024, emphasizing advances in targeting antibody lineages and augmenting CD8+ T cell responses, and highlighting sustaining funding models for HIV research and it's imperativeness for addressing broader public health issues.
HIV vaccine development, emphasizing HIV, RSV, and coronavirus COVID-19 research is discussed by Prof. Barney Graham. This information is crucial for immunologists, virologists, and those in vaccine research. Learn from cross-disciplinary strategies. You, as healthcare professionals in these fields, need to grasp these insights for innovation. HIV, RSV, and coronavirus studies offer valuable lessons. Keep up with the latest in vaccine technology.
Since 2015, cases of hepatitis E have been reported in the Bentiu camp in South Sudan, Africa, which hosts over 100,000 people displaced from conflict and flooding. The first mass reactive vaccination campaign against hepatitis E using the Hecolin® vaccine, the key ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
